Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.2217/fmb-2020-0199 http://scihub22266oqcxt.onion/10.2217/fmb-2020-0199 33709775!7958644!33709775     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33709775&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Future+Microbiol 2021 ; 16 (ä): 317-322 Nephropedia Template TP {{tp|p=33709775|t=2021. COVID-19 pneumonia: do not leave the corticosteroids behind!|pdf=|usr=}}{{33709775}} gab.com Text COVID-19 pneumonia: do not leave the corticosteroids behind! JO: Future Microbiol http://www.kidney.de/pget.php?&tw=1&pmid=33709775 #FOAvip The host inflammatory response is critical in the progression of lung injuries in patients with SARS-CoV-2. Corticosteroids (CS) have been widely used as immunomodulating agents, but the right timing, dosage and type of molecule are unknown. In fact, the early use of CS could facilitate the viral replication but late administration may not prevent the alveolar damage. Nevertheless, a short administration of high doses of CS in the early stage of the inflammatory phase resulted in favorable outcomes. Noteworthy, some inhaled CS inhibited in vitro the viral replication of SARS-CoV-2. We aimed to define the place in therapy for CS in COVID-19 infection describing the features of patients who may benefit from their administration. Twit Text FOAVip COVID-19 pneumonia: do not leave the corticosteroids behind!????Future Microbiol http://www.kidney.de/pget.php?&tw=1&pmid=33709775 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33709775 #FOAvip English Wikipedia <ref>{{Cite pmid|33709775}}</ref> COVID-19 pneumonia: do not leave the corticosteroids behind! #MMPMID33709775 Pinna SM; Scabini S; Corcione S; Lupia T; De Rosa FG Future Microbiol 2021[Mar]; 16 (ä): 317-322 PMID33709775show ga The host inflammatory response is critical in the progression of lung injuries in patients with SARS-CoV-2. Corticosteroids (CS) have been widely used as immunomodulating agents, but the right timing, dosage and type of molecule are unknown. In fact, the early use of CS could facilitate the viral replication but late administration may not prevent the alveolar damage. Nevertheless, a short administration of high doses of CS in the early stage of the inflammatory phase resulted in favorable outcomes. Noteworthy, some inhaled CS inhibited in vitro the viral replication of SARS-CoV-2. We aimed to define the place in therapy for CS in COVID-19 infection describing the features of patients who may benefit from their administration. |*COVID-19 Drug Treatment[MESH] |Administration, Inhalation[MESH] |Adrenal Cortex Hormones/administration & dosage/*therapeutic use[MESH] |Guidelines as Topic[MESH] |Humans[MESH] |Inflammation/*drug therapy/virology[MESH] |Meta-Analysis as Topic[MESH] |Randomized Controlled Trials as Topic[MESH]COVID-19 pneumonia: do not leave the corticosteroids behind!(epmc).pdf DeepDyve Pubget Overpricing